Differential expression of microRNAs as the novel potential diagnostic tool for the endometrial carcinoma

Česká verzia

Authors: L. Záveský ¹; R. Turyna ²; M. Kohoutová ¹
Authors place of work: Ústav biologie a lékařské genetiky 1. LF UK a VFN, Praha, přednostka doc. MUDr. M. Kohoutová, CSc. ¹; Ústav pro péči o matku a dítě, Praha, ředitel doc. MUDr. J. Feyereisl, CSc. ²
Published in the journal: Ceska Gynekol 2013; 78(5): 432-442
Category: Original Article

Summary

The most common gynecological malignancy, the endometrial carcinoma, is mostly diagnosed at early stages. However, diagnosis at advanced stages is accompanied by the high mortality rate. It is suggested that this cancer is one of the less studied female cancers. The necessity to establish novel diagnostic markers has led to investigations of small non-coding RNAs, particularly microRNAs, also in endometrial cancer. There have been found many microRNAs potentially associated with carcinogenesis and clinico-pathological data including prognosis for patients. Many microRNAs may also serve as diagnostic markers for non-invasive diagnostics using blood plasma. We reviewed extensively the published research focused on microRNAs that have been found deregulated particularly in tissue samples within the both major types of endometrial cancer (type 1 and type 2). They are presented in the view of their potential targets and mechanisms of action. Some microRNAs have been found deregulated also in blood plasma. There exists a high level of inconsistency across the studies as many microRNAs have been found only within one or a few studies so far. However, there are some microRNAs consistently deregulated as suggested several investigations. There remains the urgent need of more intensive research focused on the microRNAs and their regulatory role in endometrial cancer. Such a research should provide the basis for the introducing novel diagnostic tools into the clinical practice.

Keywords:
endometrial carcinoma – endometrioid –non-endometrioid – adenocarcinoma – diagnostics – prognosis – microRNA – exprese – marker – regulation

Zdroje

1. Bansal, N., Yendluri, V., Wenham, RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control, 2009, 16, p. 8–13.

2. Bokhman, JV. 2 pathogenetic types of endometrial carcinoma. Gynecol Oncol, 1983, 15, p. 10–17.

3. Boren, T., Xiong, Y., Hakam, A., et al. MicroRNAs and their target messenger RNAs associated with endometrial carcinogenesis. Gynecol Oncol, 2008, 110, p. 206–215.

4. Cohn, DE., Fabbri, M., Valeri, N., et al. Comprehensive miRNA profiling of surgically staged endometrial cancer. Am J Obstet Gynecol, 2010, 202, p. 656.e1.

5. Dai, YM., Xia, W., Song, T., et al. MicroRNa-200b is overexpressed in endometrial adenocarcinomas and enhances mmp2 activity by downregulating timp2 in human endometrial cancer cell line hec-1a cells. Nucleic Acid Ther, 2013, 23, p. 29–34.

6. Devor, EJ., Hovey, AM., Goodheart, MJ., et al. MicroRNA expression profiling of endometrial endometrioid adenocarcinomas and serous adenocarcinomas reveals profiles containing shared, unique and differentiating groups of microRNAs. Oncol Rep, 2011, 26, p. 995–1002.

7. Di Leva, G., Croce, CM. Roles of small RNAs in tumor formation. Trends Mol Med, 2010, 16, p. 257–267.

8. Doll, A., Abal, M., Rigau, M., et al. Novel molecular profiles of endometrial cancer – new light through old windows. J Steroid Biochem Mol Biol, 2008,108, p. 221–229.

9. Dušek, L., Mužík, J., Kubásek, M., et al. Epidemiologie zhoubných nádorů v České republice [online]. Masarykova univerzita, [2005], [cit. 2013-4-22]. Dostupný z WWW: http://www.svod.cz. Verze 7.0 [2007], ISSN 1802-8861.

10. Folkins, AK., Longacre, TA. Hereditary gynaecological malignancies: advances in screening and treatment. Histopathology, 2013, 62, p. 2–30.

11. Hecht, JL., Mutter, GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol, 2006, 24, p. 4783–4791.

12. Hiroki, E., Akahira, J., Suzuki, F., et al. Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas. Cancer Sci, 2010, 101, p. 241–249.

13. Hiroki, E., Suzuki, F., Akahira, J., et al. MicroRNA-34b functions as a potential tumor suppressor in endometrial serous adenocarcinoma. Int J Cancer, 2012, 131, p. E395–E404.

14. Howlader, N., Noone, AM., Krapcho, M., et al. (eds). SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2009_pops09/, based on November 2011 SEER data submission, posted to the SEER web site, 2012.

15. Huang, YW., Liu, JC., Deatherage, DE., et al. Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res, 2009, 69, p. 9038–9046.

16. Chen, XY., Yan, Q., Li, SD., et al. Expression of the tumor suppressor miR-206 is associated with cellular proliferative inhibition and impairs invasion in ER alpha-positive endometrioid adenocarcinoma. Cancer Lett, 2012, 314, p. 41–53.

17. Choi, CH., Park, YA., Choi, JJ., et al. Angiotensin II type I receptor and miR-155 in endometrial cancers: Synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cancer cells. Gynecol Oncol, 2012, 126, p. 124–131.

18. Chung, TKH., Cheung, TH., Huen, NY., et al. Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong women. Int J Cancer, 2009, 124, p. 1358–1365.

19. Chung, TKH., Lau, TS., Cheung, TH., et al. Dysregulation of microRNA-204 mediates migration and invasion of endometrial cancer by regulating FOXC1. Int J Cancer, 2012, 130, p. 1036–1045.

20. Iorio, MV., Croce, CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med, 2012, 4, p. 143–159.

21. Jiang, FZ., Liu, T., He, YY., et al. MiR-125b promotes proliferation and migration of type II endometrial carcinoma cells through targeting TP53INP1 tumor suppressor in vitro and in vivo. Bmc Cancer, 2011, 11, p. 425.

22. Karaayvaz, M., Zhang, C., Liang, SR., et al. Prognostic significance of miR-205 in endometrial cancer. Plos One, 2012, p. 7.

23. Lee, H., Choi, HJ., Kang, CS., et al. Expression of miRNAs and PTEN in endometrial specimens ranging from histologically normal to hyperplasia and endometrial adenocarcinoma. Mod Pathol, 2012, 25, p. 1508–1515.

24. Lee, JW., Park, YA., Choi, JJ., et al. The expression of the miRNA-200 family in endometrial endometrioid carcinoma. Gynecol Oncol, 2011, 120, p. 56–62.

25. Myatt, SS., Wang, J., Monteiro, LJ., et al. Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Re., 2010, 70, p. 367–377.

26. Panda, H., Chuang, TD., Luo, XP., Chegini, N. Endometrial miR-181a and miR-98 expression is altered during transition from normal into cancerous state and target PGR, PGRMC1, CYP19A1, DDX3X, and TIMP3. J Clin Endocrinol Metab, 2012, 97, p. E1316–E1326.

27. Park, YA., Lee, JW., Choi, JJ., et al. The interactions between MicroRNA-200c and BRD7 in endometrial carcinoma. Gynecol Oncol, 2012, 124, p. 125–133.

28. Qin, XY., Yan, L., Zhao, XB., et al. microRNA-21 overexpression contributes to cell proliferation by targeting PTEN in endometrioid endometrial cancer. Oncol Lett, 2012, 4, p. 1290–1296.

29. Ramon, LA., Braza-Boils, A., Gilabert, J., et al. MicroRNAs related to angiogenesis are dysregulated in endometrioid endometrial cancer. Hum Reprod, 2012, 27, p. 3036–3034.

30. Ratner, ES., Tuck, D., Richter, C., et al. MicroRNA signatures differentiate uterine cancer tumor subtypes. Gynecol Oncol, 2010, 118, p. 251–257.

31. Siegel, R., Naishadham, D., Jemal, A. Cancer statistics, 2012. Cancer J Clin, 2012, 62, p. 10–29.

32. Snowdon, J., Zhang, X., Childs, T., et al. The microRNA-200 family is upregulated in endometrial carcinoma. Plos One, 2011, 6, e22828.

33. Teague, EMCO., Van der Hoek, KH., Van der Hoek, MB.,et al. MicroRNA-regulated pathways associated with endome-triosis. Mol Endocrinol, 2009, 23, p. 265–275.

34. Torres, A., Torres, K., Pesci, A., et al. Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endome-trial carcinoma. BMC Cancer, 2012, p. 369.

35. Torres, A., Torres, K., Pesci, A., et al. Diagnostic and prognostic significance of miRNA signatures in tissues and plasma of endometrioid endometrial carcinoma patients. Int J Cancer, 2013, 132, p. 1633–1645.

36. Tsuruta, T., Kozaki, K., Uesugi, A., et al. miR-152 Is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer. Cancer Res, 2011, 71, p. 6450–6462.

37. Wu, YJ, Liu, SP., Xin, H., et al. Up-regulation of MicroRNA-145 Promotes differentiation by repressing OCT4 in human endometrial adenocarcinoma cells. Cancer, 2011, 117, p. 3989–3998.

38. Yu, DQ, Zhou, HJ., Xun, QY., et al. MicroRNA-103 regulates the growth and invasion of endometrial cancer cells through the downregulation of tissue inhibitor of metalloproteinase 3. Oncol Lett, 2012, 3, p. 1221–1226.

39. Zhou, J., Song, TR., Gong, M., et al. MicroRNA regulation of the expression of the estrogen receptor in endometrial cancer. Mol Med Rep, 2010, 3, p. 387–392.

40. Zhou, HJ., Xu, XF., Xun, QY., et al. MicroRNA-30c negatively regulates endometrial cancer cells by targeting metastasis-associated gene-1. Oncol Rep, 2012, 27, p. 807–812.